Format

Send to

Choose Destination
Clin Kidney J. 2012 Feb;5(Suppl 1):i25-i38. doi: 10.1093/ndtplus/sfr165.

Magnesium in disease.

Author information

1
Klinikum der J.W. Goethe-Universität, Medizinische Klinik III/Nephrologie, Frankfurt/Main, Germany.
2
Universitätsklinik Würzburg, Medizinische Klinik und Poliklinik I, Würzburg, Germany.

Abstract

Although the following text will focus on magnesium in disease, its role in healthy subjects during physical exercise when used as a supplement to enhance performance is also noteworthy. Low serum magnesium levels are associated with metabolic syndrome, Type 2 diabetes mellitus (T2DM) and hypertension; consequently, some individuals benefit from magnesium supplementation: increasing magnesium consumption appears to prevent high blood pressure, and higher serum magnesium levels are associated with a lower risk of developing a metabolic syndrome. There are, however, conflicting study results regarding magnesium administration with myocardial infarction with and without reperfusion therapy. There was a long controversy as to whether or not magnesium should be given as a first-line medication. As the most recent trials have not shown any difference in outcome, intravenous magnesium cannot be recommended in patients with myocardial infarction today. However, magnesium has its indication in patients with torsade de pointes and has been given successfully to patients with digoxin-induced arrhythmia or life-threatening ventricular arrhythmias. Magnesium sulphate as an intravenous infusion also has an important established therapeutic role in pregnant women with pre-eclampsia as it decreases the risk of eclamptic seizures by half compared with placebo.

KEYWORDS:

cardiovascular disease; diabetes mellitus; magnesium; metabolic syndrome; pre-eclampsia/eclampsia

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center